Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06054867 · ClinicalTrials.gov registry record · NA
PRCT002 PRostate Cancer Treatment With the AQUABEAM Robotic System
A NA study of Localized Prostate Cancer, sponsored by PROCEPT BioRobotics.
- Active
- Registry status
- NA
- Development phase
- 22
- Enrollment target
- 3
- Study locations
NCT06054867: Active NA study of Localized Prostate Cancer, sponsored by PROCEPT BioRobotics.
NCT06054867 is a NA study of Localized Prostate Cancer that is active but no longer recruiting, run by PROCEPT BioRobotics. The registered enrollment target is 22 participants, below the 114-participant average among 6 other Localized Prostate Cancer trials with a reported enrollment target (81% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06054867, a NA study of Localized Prostate Cancer, is active but no longer recruiting, sponsored by PROCEPT BioRobotics.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 22 participants
- Enrollment target
- 3
- Study locations
Study Summary
The goal of this clinical trial is to evaluate the safety of the AQUABEAM Robotic System in treating patients with localized prostate cancer. Participants will go through baseline and follow up assessments up to 12 months.
Conditions Studied
Interventions
- DEVICE Robotic Waterjet Treatment
Study Locations (3)
California
- University of Southern California, Institute of Urology - Los Angeles
Illinois
- NorthShore University HealthSystem - Glenview
New York
- NYU Grossman School of Medicine - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2024-03-11 |
| Est. Completion | 2025-04 |
| Phase | NA |
What the registry record for NCT06054867 still lists
NCT06054867 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 114-participant average among 6 other Localized Prostate Cancer trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Localized Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Robotic Waterjet Treatment is the first listed.
NCT06054867 reports a single indexed study location in California, Illinois, New York.
Frequently Asked Questions
What is clinical trial NCT06054867 about?
NCT06054867 is a clinical study titled "PRCT002 PRostate Cancer Treatment With the AQUABEAM Robotic System". The goal of this clinical trial is to evaluate the safety of the AQUABEAM Robotic System in treating patients with localized prostate cancer. Participants will go through baseline and follow up assessments up to 12 months.
What is the current status of trial NCT06054867?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 22 participants. The study started on 2024-03-11. Estimated completion is 2025-04.
What conditions does trial NCT06054867 study?
This clinical trial studies the following conditions: Localized Prostate Cancer.
What interventions are being tested in trial NCT06054867?
The interventions under investigation include: Robotic Waterjet Treatment (DEVICE).
Who is sponsoring clinical trial NCT06054867?
This trial is sponsored by PROCEPT BioRobotics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06054867 being conducted?
This trial has 3 study locations across California, Illinois, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Localized Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
WATER IV Prostate Cancer
RECRUITING · NA
-
PRCT001 Aquablation theraPy Outcomes in pRostate Cancer patienTs
ACTIVE NOT RECRUITING · NA
-
18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy
RECRUITING · Phase 2
-
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
RECRUITING · Phase 2
-
Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostate Cancer.
ACTIVE NOT RECRUITING · Phase 2
-
Use of Recombinant Adenovirus Therapy to Treat Localized Prostate Cancer
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI